Ocaperidone

Ocaperidone

Names
IUPAC name 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one
Identifiers
CAS Number	129029-23-8
3D model (Jmol)	Interactive image
ChemSpider	64451
IUPHAR/BPS	46
KEGG	D02675
MeSH	C072259
PubChem CID	71351
InChI InChI=1S/C24H25FN4O2/c1-15-4-3-10-29-23(15)26-16(2)19(24(29)30)9-13-28-11-7-17(8-12-28)22-20-6-5-18(25)14-21(20)31-27-22/h3-6,10,14,17H,7-9,11-13H2,1-2H3 Key: ZZQNEJILGNNOEP-UHFFFAOYSA-N InChI=1/C24H25FN4O2/c1-15-4-3-10-29-23(15)26-16(2)19(24(29)30)9-13-28-11-7-17(8-12-28)22-20-6-5-18(25)14-21(20)31-27-22/h3-6,10,14,17H,7-9,11-13H2,1-2H3 Key: ZZQNEJILGNNOEP-UHFFFAOYAT
SMILES CC1=CC=CN2C1=NC(=C(C2=O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F)C
Properties
Chemical formula	C24H25FN4O2
Molar mass	420.49 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Ocaperidone (also R 79598) is a benzisoxazole antipsychotic. It was initially developed by Janssen, later licensed to French laboratory Neuro3D and then acquired in 2007 by German company Evotec. Its testing was abandoned after phase II trials, as of 22 February 2010.